Preoperative immunostimulation with propionibacterium avidum KP-40 in patients with gastric carcinoma: a prospective randomized study.
Sixty-eight patients admitted for resection of gastric carcinoma entered a prospectively randomized trial. Patients in the therapy group (n = 34) received a preoperative controlled infusion of 10 mg Propionibacterium avidum KP-40. The therapy and control group did not differ with regard to postoperative complications, tumor recurrence rates (therapy group: 41%, control group: 38%), and patient survival rates (survival rate in the therapy group after 25 months: 53%, in the control group after 25 months: 50%).
Peters
K M
KM
Orthopädische Klinik, RWTH Aachen.
Beuth
J
J
Ko
H L
HL
Pulverer
G
G
Kluger
J
J
Grundmann
R
R
D000230:Adenocarcinoma / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007108:Immune Tolerance / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D011424:Propionibacterium / Q000276:immunology*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy*
D000276:Adjuvants, Immunologic